samedan logo
 
 
 
spacer
home > ebr > spring 2008 > mass spectrometry for the next generation
PUBLICATIONS
European Biopharmaceutical Review

Mass Spectrometry for the Next Generation

High performance mass spectrometry advances provide powerful new research capabilities with sophisticated software solutions to biopharmaceuticals. Michael Willett of Bruker Corporation informs us of the latest developments in this cutting-edge technology

In the past year, major new developments in cutting-edge, highend mass spectrometers and mass spectrometry-based software solutions have reached research scientists in the pharmaceutical and biotechnology industries, positively impacting their research. A new generation of proteomics data warehousing, proteomics data mining and proteomics project management software is now in use by research scientists, especially in Europe. Secondly, new tools for biologics drug development have become available. In addition, mass spectrometry-based metabolic profiling is now combining complementary methods of metabolite quantitation and structure determination by nuclear magnetic resonance (NMR) with exact mass analysis by electrospray mass spectrometry (ESI-MS). Furthermore, new generations of highend mass spectrometers have now become particularly useful to pharma and biotech researchers dedicated to drug discovery and development, especially when coupled with the latest advanced solutions in MALDI molecular imaging of human and research model tissues, along with software solutions for biomarker panel discovery, identification and validation, for example.

NEW PROTEOMICS DATA WAREHOUSING AND PROJECT MANAGEMENT SOFTWARE PRODUCE POSITIVE PROTEIN RESEARCH RESULTS

With a new generation of proteomics data warehousing software now in use, next-generation bioinformatics platforms addressing scientists’ current needs in proteomics identification and biomarker profiling, quantification and validation have become available. As a comprehensive solution for qualitative and quantitative liquid chromatography (LC)-MS/MS protein analysis, such proteomics software can now support all current label chemistries including multiplexed labels, as well as label-free quantification. Interactive validation of protein quantification based on raw LC/MS data has become simple and straightforward, streamlining the discovery process through decoy auto-validation algorithms and algorithms that produce non-redundant protein result lists across entire proteomics projects, including brain proteomics projects.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Willett has been the Public relations and Investor Relations Officer of Bruker Corporation since September 2002, and was the Investor Relations Director at Bruker Daltonics from 2000 to 2002. Prior to joining Bruker Daltonics, Michael was the International Finance, Tax and Accounting Manager at a leading healthcare policy consulting firm from 1998 to 2000. Previously, he was IR Director at a computer company for five years. Early in his career, Michael was an Audit Manager with Ernst & Young LLP in New York, Barcelona and Zurich. A CPA, he holds a BA and a BSE from the University of Connecticut, and an MBA from Columbia University, followed by post-MBA study at Northwestern University in Chicago.
spacer
Michael Willett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement